Clinical aproach to the patient with chronic hepatitis C infection and normal aminotransferases

Annals of Hepatology

Volumn 9, Issue SUPPL. 1, 2010, Pages 72-79

  Zapata, Rodrigo ^a  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Antiviral therapy; Chronic hepatitis C; Normal ALT; Persistently normal alanine aminotransferase; PNALT

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; PRACTICE GUIDELINE; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS TITRATION; BLOOD; CHRONIC HEPATITIS; DRUG COMBINATION; ENZYME ASSAY; ENZYMOLOGY; HOSPITALIZATION; LIVER; LIVER CIRRHOSIS; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CLINICAL ENZYME TESTS; DRUG THERAPY, COMBINATION; HEPATITIS, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; LIVER CIRRHOSIS; PATIENT SELECTION; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79952112374     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31728-4     Document Type: Article

References (50)

1. NIH consensus statement on management of hepatitis C. NIH Consensus, State Sci statements 2002, 19: 1-46.
2. Anonymous, global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepatitis 1999; 6: 35-47.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, Management, and Treatment of Hepatitis C: An Update. AASLD practice guidelines. Hepatology 2009; 49: 1335-1374.
4. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31: 9-16.
5. Alberti A, Noventa F, Benvegnù L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic individuals with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-964.
6. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995; 123: 330-337.
7. Puoti C, Castellacci R, Montagnese F. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? Dig Liver Dis 2000; 32: 634-643.
8. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-1398.
9. Prati D, Shiffman ML, Diago M, Gane E, Rajender Reddy K, Pockros P, et al. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol 2006; 44: 679-685.
10. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998; 27: 1213-1219.
11. Puoti C. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. J Hepatol 2003; 38: 529-532.
12. Zeuzem S, Alberti A, Rosenberg W, Marcellin P, Daigo M, Negro F, Prati D, et al. Review article: Management of patients with chronic hepatitis C virus infection and normal alanine aminotrasferase activity. Aliment Pharmacol Ther 2006; 24: 1133-1149.
13. Prati D, Taioli E, Zanella A, della Torre E, Butelli S, del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
14. Puoti C, Guido M, Mangia A, Persico M, Prati D. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003; 35: 362-369.
15. Seeff LB. The natural history of chronic hepatitis C virus infection. Clin Liver Dis 1997; 1: 587-602.
16. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(Supl. 1): S35-S46.
17. Ascione A, Tartaglione T, Di Constanzo GG. Natural history of chronic hepatitis C infection. Dig Liv Dis 2007; 39(Suppl 1); S4-S7.
18. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760-764.
19. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al. Prospective study on antihepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 1000-1005.
20. Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, et al. Chronic hepatitis C in patients with persisten tly normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4: 645-652.
21. Marcellin P, Martinot M, Boyer N, Levy S. Treatment of hepatitis C patients with normal aminotransferase levels. Clin Liver Dis 1999; 3: 843-853.
22. Persico M, Perrotta S, Persico E, Terracciano L, Folgori A, Ruggeri L, Nicosia A. Hepatitis C vírus carriesrs with persistently normal ALT levels: Biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepatitis 2006; 13: 290-296.
23. Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 2005; 3(10 Suppl. 2): S89-S91.
24. Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami N, Bellis L, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117-123.
25. Lawson A. On behalf of the Trent Hepatitis C Study Group. Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease? J Viral Hepatitis 2010; 17; 51-58.
26. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
27. Shaheen AAM, Wan AF, Myers RP. Fibro Test and Fibro scan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastro 2007; 102: 2589-2600.
28. Aita JS, Harrison SA. Liver biopsy versus non invasive testing in chronic hepatitis C: Where do we stand in 2008? Current Hepatitis Reports 2008; 7: 51-59.
29. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
30. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838-845.
31. Sebastini G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepatitis 2008; 15: 212-218.
32. Okanoue T, Itoh Y, Minami M, Hashimoto H, Yasui K, Yotsuyanagi H, Takehara T et al. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatology Research 2008; 38(2): 217.
33. Fried MW. Hepatitis C infection with normal liver chemistry tests. Clin Gastroenterol Hepatol 2008; 6: 503-505.
34. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology. 2002; 36(5 Suppl. 1): S179-S184.
35. Puoti C. Hepatitis C virus with normal transaminase levels. Dig Dis 2007; 25: 277-278.
36. Tassopoulos NC. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 1999; 31(Suppl. 1): 193-196.
37. Marcellin P, Lévy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26 (3 Suppl. 1):133S-136S.
38. Bini EJ, Mehandru S. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther 2006; 23: 777-785.
39. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-1732.
40. Arora S, O'Brien C, Zeuzem S, Schiffman ML, Diago M, Tran A, Pockros PJ, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon á-2a (40 kDa) plus ribavirin: Impact on health-related quality of life. J Gastroenterol Hepatol 2006; 21: 406-412.
41. Puoti C, Pellicelli AM, Romano M, Mecenate F, Guarisco R, Barbarini G, Mazzoni E, et al. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study. Liver Int 2009; 29: 1479-1484.
42. Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med 2009; 360: 1902-1906.
43. Wilck MB, Hamel MB, Baden LR. Clinical decisions. Management of incidental hepatitis C virus infection-polling results. N Engl J Med 2009; 360: e30-e31.
44. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman, R, McNair L, et al. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. N Engl J Med 2009; 360: 1827-1838.
45. Puoti C, Bellis L, Guarisco R, Unto OD, Spilabotti L, Costanza OM. HCV carriers with normal alanine aminotransferase levels: Healthy persons or severely ill patients? Dealing with an everyday clinical problem. Eur J Intern Med 2010; 21: 57-61.
46. Deuffic-Burban S, Babany G, Lonjon-Domanec I, Deltenre P, Canva-Delcambre V, Dharancy S, et al. Impact of pegylated interferon and ribavirin on morbidity and mortality inpatients with chronic hepatitis C and normal aminotransferases in France. Hepatology 2009; 50: 1351-1359.
47. Renou C, Halfon P, Pol S, Cacoub P, Jouve E, Bronowickii PG, Arpurt PP, et al. Histological feaures and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002; 51: 585-590.
48. Hui CK, Zhang HY, Shek T, Yaos H, Yueng YH, Leung KW, Lai ST, et al. Disease progression in Chinese chronic hepatitis C patients with persistently normal alanine aminotransferase levels. Alimentary Pharmacol Ther 2007; 25: 1283-1292.
49. Jamal MM, Soni A, Quin PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30: 1307-1311.
50. Hervé S, Savoye G, Riachi G, Hellot M, Goria O, Lerebours E, Colin R, Ducrotte P. Chronic hepatitis C with persistently normal or abnormal aminotransferase levels: is it the same entity? Eur J Gastroenterol Hepatol 2001; 13: 495-500.